医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nagoya Anesthesia Clinic Initiates Inbound Medical Treatment for Treatment-Resistant Depression and Intractable Chronic Pain Using Ketamine

2023年10月24日 AM10:00
このエントリーをはてなブックマークに追加


 

NAGOYA, Japan

Nagoya Anesthesia Clinic (https://nagoyamasui.com/), located in Nagoya City, Aichi Prefecture, Japan, has commenced inbound medical treatment for treatment-resistant depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and intractable chronic pain, utilizing the groundbreaking drug, Ketamine, starting in October 2023. In addition, the clinic offers other innovative procedures such as Echo-Guided Botox treatment for stiff neck and EchoGuided PRP therapy for tennis elbow.

Ketamine, a widely used general anesthetic dating back to over 50 years ago, has also been employed in the United States for the treatment of mental disorders and chronic pain for the past decade. Unlike conventional medications, which can take time to alleviate symptoms, Ketamine offers rapid symptom relief within hours to up to three weeks of administration. Moreover, it is associated with minimal long-term side effects, making it a promising treatment modality.

Nagoya Anesthesia Clinic, with its rich experience of performing over 1000 Ketamine infusions for various pain and mental disorders, has launched the Ketamine Clinic based on Ketamine’s potent analgesic and antidepressant properties. Ketamine infusions are typically administered in sets of 3 to 6 sessions over a span of 1 to 3 weeks, followed by a maintenance therapy once a month, a regimen notable for its low incidence of long-term side effects.

Nagoya Anesthesia Clinic is proud to be the first and only Ketamine Clinic in Japan and will begin accepting patients for inbound medical treatment of treatment-resistant depression, OCD, PTSD, and intractable chronic pain from October 2023. Building upon their Ketamine infusion experience dating back to 2010, they aim to support individuals struggling with treatment-resistant conditions through innovative, evidence-based, and compassionate approaches.

Nagoya Anesthesia Clinic “Ketamine Clinic” Information Page:
https://nagoyamasui.com/ketamine3

“Stiff Neck Botox” Information Page:
https://nagoyamasui.com/botox3

“Tennis Elbow PRP Therapy” Information Page:
https://nagoyamasui.com/prp3

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012741647/en/

CONTACT

For inquiries, please contact:

JTB Medical & Healthcare:

jmhc_info@j-medical-healthcare.com

同じカテゴリーの記事 

  • AMLにおける寛解期に残存するFLT3-ITD変異と移植後の転帰との間に重要な関連があることが研究によって判明
  • 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系
  • ベイジーン、2024年第1四半期決算および事業に関する最新情報を発表
  • Qihan Biotech Appoints Yingyong Xu as its Chief Medical Officer
  • 武田薬品工業: 2023年度通期業績および2024年度の見通しを公表 – 後期段階のパイプライン開発とCore営業利益率改善へのコミットメントを強調